infigratinib
Commercial- Indications
- Cholangiocarcinoma, Achondroplasia, Hypochondroplasia
Company intelligence / Profile preview
QED Therapeutics
Palo Alto, California, United Statesqedtx.com ↗
- Ownership
- Private
- Employees
- ~50
- Development stage
- Commercial
01
Overview
QED Therapeutics has developed infigratinib (BGJ398), an orally administered selective inhibitor of FGFR1–3. Infigratinib received FDA breakthrough therapy designation for achondroplasia and has shown meaningful clinical activity in chemotherapy-refractory cholangiocarcinoma with FGFR2 fusions. The company’s current focus centers on rare skeletal dysplasias such as achondroplasia and hypochondroplasia. Recent clinical results include positive feedback from regulatory agencies regarding pivotal trials and promising Phase II data in pediatric achondroplasia patients.[1][6]
- Therapeutic areas
- OncologyRare Diseases
- Modalities
- Small molecules (notably FGFR kinase inhibitors)[4][5]
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
Helsinn Group—strategic collaboration to co-develop/commercialize infigratinib outside the U.S. for oncology indications; BridgeBio retains rights to skeletal dysplasias.[2]
Beyond the preview
Go deeper on QED Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on QED Therapeutics.